

Helena Marzo-Ortega

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7029123/publications.pdf>

Version: 2024-02-01

159
papers

11,285
citations

53660

45
h-index

30010

103
g-index

159
all docs

159
docs citations

159
times ranked

7693
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 978-991.	0.5	1,220
2	Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. <i>Nature Genetics</i> , 2011, 43, 761-767.	9.4	778
3	European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 499-510.	0.5	743
4	Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1520-1527.	0.5	719
5	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 700.1-712.	0.5	609
6	European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 4-12.	0.5	405
7	EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1327-1339.	0.5	402
8	Efficacy of etanercept in the treatment of the enthesal pathology in resistant spondylarthropathy: A clinical and magnetic resonance imaging study. <i>Arthritis and Rheumatism</i> , 2001, 44, 2112-2117.	6.7	399
9	Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1958-1963.	0.5	383
10	Severity of baseline magnetic resonance imaging "evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. <i>Arthritis and Rheumatism</i> , 2008, 58, 3413-3418.	6.7	323
11	Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. <i>Lancet, The</i> , 2017, 389, 2317-2327.	6.3	316
12	Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 382-385.	0.5	313
13	Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination. <i>Vaccines</i> , 2021, 9, 435.	2.1	284
14	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 986-991.	0.5	240
15	Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1016-1023.	0.5	188
16	The role of biomechanical factors and HLA-B27 in magnetic resonance imaging-determined bone changes in plantar fascia enthesopathy. <i>Arthritis and Rheumatism</i> , 2002, 46, 489-493.	6.7	182
17	A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial. <i>Journal of Rheumatology</i> , 2016, 43, 1724-1734.	1.0	175
18	MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1550-1558.	0.5	171

#	ARTICLE	IF	CITATIONS
19	Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 830-835.	0.5	161
20	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. <i>Nature Communications</i> , 2015, 6, 6046.	5.8	149
21	Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1568-1575.	0.5	143
22	Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. <i>Lancet, The</i> , 2020, 395, 53-64.	6.3	138
23	Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 571-592.	0.5	137
24	Baseline and 1-year magnetic resonance imaging of the sacroiliac joint and lumbar spine in very early inflammatory back pain. Relationship between symptoms, HLA-B27 and disease extent and persistence. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1721-1727.	0.5	134
25	Brief Report: Group 3 Innate Lymphoid Cells in Human Enthesis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1816-1822.	2.9	121
26	Evaluation of the diagnostic utility of spinal magnetic resonance imaging in axial spondylarthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 1331-1341.	6.7	116
27	Evidence that tissue resident human entheses $\gamma\delta$ T-cells can produce IL-17A independently of IL-23R transcript expression. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1559-1565.	0.5	109
28	Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 74-76.	0.5	100
29	Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1311-1317.	0.5	85
30	Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. <i>Lancet, The</i> , 2018, 392, 134-144.	6.3	81
31	Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study. <i>Arthritis Care and Research</i> , 2017, 69, 1020-1029.	1.5	79
32	Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis. <i>Arthritis Care and Research</i> , 2016, 68, 838-844.	1.5	73
33	The Early Phases of Ankylosing Spondylitis: Emerging Insights From Clinical and Basic Science. <i>Frontiers in Immunology</i> , 2018, 9, 2668.	2.2	73
34	Identification of myeloid cells in the human entheses as the main source of local IL-23 production. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 929-933.	0.5	70
35	Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1387-1393.	0.5	69
36	Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. <i>RMD Open</i> , 2017, 3, e000592.	1.8	68

#	ARTICLE	IF	CITATIONS
37	PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1882-1885.	0.5	64
38	Magnetic resonance imaging in the assessment of metacarpophalangeal joint disease in early psoriatic and rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2009, 38, 79-83.	0.6	63
39	Tumour necrosis factor- α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2016, 20, 1-334.	1.3	62
40	Brief Report: Magnetic Resonance Imaging Assessment of Axial Psoriatic Arthritis: Extent of Disease Relates to HLA-B*27. <i>Arthritis and Rheumatism</i> , 2013, 65, 2274-2278.	6.7	59
41	Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 193-201.	0.5	59
42	The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 123-134.	1.3	54
43	Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 778-781.	0.5	53
44	Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1034-1042.	0.5	53
45	Evidence for a different anatomic basis for joint disease localization in polymyalgia rheumatica in comparison with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 3496-3501.	6.7	49
46	Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1168-1174.	0.5	49
47	Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1). <i>RMD Open</i> , 2021, 7, e001546.	1.8	46
48	Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci. , 2020, 61, 3.		43
49	Emergence of severe spondyloarthropathy-related enthesal pathology following successful vedolizumab therapy for inflammatory bowel disease. <i>Rheumatology</i> , 2019, 58, 963-968.	0.9	42
50	BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222 Td	0.9	41
51	New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice. <i>Therapeutic Advances in Chronic Disease</i> , 2018, 9, 77-87.	1.1	40
52	Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 38.	1.6	38
53	Association of Toll-like receptor 4 (TLR4) with chronic plaque type psoriasis and psoriatic arthritis. <i>Archives of Dermatological Research</i> , 2016, 308, 201-205.	1.1	35
54	Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set: translation and cross-cultural adaptation into 15 languages. <i>RMD Open</i> , 2016, 2, e000311.	1.8	31

#	ARTICLE	IF	CITATIONS
55	Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades. <i>RMD Open</i> , 2021, 7, e001888.	1.8	30
56	A randomized controlled trial of early intervention with intraarticular corticosteroids followed by sulfasalazine versus conservative treatment in early oligoarthritis. <i>Arthritis and Rheumatism</i> , 2007, 57, 154-160.	6.7	28
57	Is minocycline therapy in acne associated with antineutrophil cytoplasmic antibody positivity? A cross-sectional study. <i>British Journal of Dermatology</i> , 2007, 156, 1005-1009.	1.4	28
58	Axial Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 327-341.	0.8	23
59	Non-radiographic <i>vs</i> radiographic axSpA: what are the differences in a name?. <i>Rheumatology</i> , 2020, 59, iv18-iv24.	0.9	22
60	Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: An ancillary study of the ASAS-COMOSPA project. <i>Joint Bone Spine</i> , 2018, 85, 447-453.	0.8	21
61	Increased Risk of Hypertension Associated with Spondyloarthritis Disease Duration: Results from the ASAS-COMOSPA Study. <i>Journal of Rheumatology</i> , 2019, 46, 701-709.	1.0	21
62	The Use of Magnetic Resonance Imaging in Axial Spondyloarthritis: Time to Bridge the Gap Between Radiologists and Rheumatologists. <i>Journal of Rheumatology</i> , 2017, 44, 780-785.	1.0	20
63	Magnetic resonance imaging in spondyloarthritis. <i>Current Opinion in Rheumatology</i> , 2010, 22, 381-387.	2.0	19
64	5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. <i>Lancet Rheumatology</i> , The, 2020, 2, e339-e346.	2.2	19
65	Short-term Repeat Magnetic Resonance Imaging Scans in Suspected Early Axial Spondyloarthritis Are Clinically Relevant Only in HLA-B27 positive Male Subjects. <i>Journal of Rheumatology</i> , 2018, 45, 202-205.	1.0	18
66	The concept of disease modification in spondyloarthropathy. <i>Journal of Rheumatology</i> , 2002, 29, 1583-5.	1.0	18
67	The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2018, 10, 169-180.	1.2	16
68	Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis. <i>Rheumatology and Therapy</i> , 2019, 6, 435-450.	1.1	16
69	Three-dimensional nail imaging by optical coherence tomography: a novel biomarker of response to therapy for nail disease in psoriasis and psoriatic arthritis. <i>Clinical and Experimental Dermatology</i> , 2019, 44, 462-465.	0.6	16
70	Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK. <i>Pharmacoeconomics</i> , 2018, 36, 1015-1027.	1.7	15
71	Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling. <i>Arthritis and Rheumatology</i> , 2022, 74, 1535-1543.	2.9	15
72	Michelangelo and Medicine. <i>Journal of the Royal Society of Medicine</i> , 2002, 95, 514-515.	1.1	14

#	ARTICLE	IF	CITATIONS
73	The Relationship Between Physical Examination and Ultrasonography of Large Entheses of the Achilles Tendon and Patellar Tendon Origin. <i>Journal of Rheumatology</i> , 2020, 47, 1026-1030.	1.0	14
74	Evidence of response to IL-6 inhibition in some cases of refractory spondyloarthritis-associated peripheral synovitis: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1418-1420.	0.5	13
75	Minocycline induced autoimmune disease in rheumatoid arthritis: a missed diagnosis?. <i>Journal of Rheumatology</i> , 2001, 28, 377-8.	1.0	13
76	Vascularity of nail bed by ultrasound to discriminate psoriasis, psoriatic arthritis and healthy controls. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 872.	0.4	13
77	Poor awareness of inflammatory back pain and axial spondyloarthritis among secondary care specialists. <i>Clinical Rheumatology</i> , 2016, 35, 2627-2628.	1.0	12
78	Serum IL-7 as diagnostic biomarker for rheumatoid arthritis, validation with EULAR 2010 classification criteria. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 115-120.	0.4	12
79	Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies. <i>Rheumatology and Therapy</i> , 2021, 8, 273-288.	1.1	11
80	Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry. <i>Rheumatology</i> , 2021, 60, 5795-5800.	0.9	10
81	A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis. <i>Rheumatology and Therapy</i> , 2021, 8, 1775-1787.	1.1	10
82	Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 490-495.	0.5	10
83	The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 303.	0.8	9
84	Screening psoriatic arthritis tools: analysis of the Early Arthritis for Psoriatic Patients questionnaire. <i>Rheumatology</i> , 2015, 54, 200-202.	0.9	8
85	Receptor activator of nuclear factor kappa- β ligand (RANKL) serum levels are associated with progression to seropositive/negative rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 456-462.	0.4	8
86	The impact of gender and sex on diagnosis, treatment outcomes and health-related quality of life in patients with axial spondyloarthritis. <i>Clinical Rheumatology</i> , 2022, 41, 3573-3581.	1.0	8
87	MRI of psoriatic nail disease pre- and post-TNF inhibitor therapy shows persistent subclinical inflammation after 6 months despite good clinical response. <i>RMD Open</i> , 2018, 4, e000599.	1.8	7
88	Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial. <i>Rheumatology and Therapy</i> , 2021, 8, 135-150.	1.1	7
89	A comparison of apremilast monotherapy and combination therapy for psoriatic arthritis in a real-life setting: Data from the Leeds Combined Psoriatic Service. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1796-1798.	0.6	6
90	Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks. <i>Rheumatology and Therapy</i> , 2020, 7, 759-774.	1.1	6

#	ARTICLE	IF	CITATIONS
91	Chest pain mimicking pulmonary embolism may be a common presentation of COVID-19 in ambulant patients without other typical features of infection. <i>Journal of Internal Medicine</i> , 2021, 290, 349-358.	2.7	6
92	Arthritis and enthesitis in the hip and pelvis region in spondyloarthritis - OMERACT validation of two whole-body MRI methods. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 940-945.	1.6	6
93	Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 566-574.	0.4	6
94	Interferon-related gene expression in response to TNF inhibitor treatment in ankylosing spondylitis patients: a pilot study. <i>Rheumatology</i> , 2021, 60, 3607-3616.	0.9	5
95	Etanercept treatment in resistant spondyloarthropathy: imaging, duration of effect and efficacy on reintroduction. <i>Clinical and Experimental Rheumatology</i> , 2002, 20, S175-7.	0.4	5
96	Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky036.	0.3	4
97	Consenso ASAS en nomenclatura en espa�ol para las espondiloartritis. <i>Reumatolog�a Cl�nica</i> , 2020, 16, 333-338.	0.2	4
98	Axial spondyloarthritis: coming of age. <i>Rheumatology</i> , 2020, 59, iv1-iv5.	0.9	4
99	�Too much of a good thing�: can network meta-analysis guide treatment decision-making in psoriatic arthritis?. <i>Rheumatology</i> , 2021, 60, 3042-3044.	0.9	4
100	British Association of Sexual Health and HIV national guideline on the management of sexually acquired reactive arthritis 2021. <i>International Journal of STD and AIDS</i> , 2021, 32, 095646242110202.	0.5	4
101	Joint and enthesal inflammation in the knee region in spondyloarthritis - reliability and responsiveness of two OMERACT whole-body MRI scores. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 933-939.	1.6	4
102	Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial spondyloarthritis. <i>Rheumatology</i> , 2022, 61, 2054-2062.	0.9	4
103	Poor health and functioning in patients with axial spondyloarthritis during the COVID-19 pandemic and lockdown: REUMAVID study (phase 1). <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2110666.	1.2	4
104	Early Oligoarthritis. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 627-639.	0.8	3
105	Association of Diverticulitis with Prolonged Spondyloarthritis: An Analysis of the ASAS-COMOSPA International Cohort. <i>Journal of Clinical Medicine</i> , 2019, 8, 281.	1.0	3
106	Axial spondyloarthritis: time to stop the split 10 years on. <i>Nature Reviews Rheumatology</i> , 2020, 16, 5-6.	3.5	3
107	Systematic literature review of non-topical treatments for early, untreated (systemic therapy na�ve) psoriatic disease: a GRAPPA initiative. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa032.	0.3	3
108	Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52�weeks. <i>BMC Rheumatology</i> , 2021, 5, 50.	0.6	3

#	ARTICLE	IF	CITATIONS
109	Correspondence on "No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related " physician-reported spondylitis"™?â€™. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e185-e185.	0.5	3
110	Acute Unilateral Sacroiliitis Mimicking Infection on Magnetic Resonance Imaging with Response to Nonsteroidal Antiinflammatory Drugs: A Distinct Presentation of Spondyloarthritis?. <i>Journal of Rheumatology</i> , 2018, 45, 1708-1710.	1.0	2
111	Comment on: Emergence of severe spondyloarthropathy-related enthesal pathology following successful vedolizumab therapy for inflammatory bowel disease: reply. <i>Rheumatology</i> , 2019, 58, 1115-1117.	0.9	2
112	Correspondence on "Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial"™. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e164-e164.	0.5	2
113	Ixekizumab: an IL-17A inhibitor for the treatment of axial Spondylarthritis. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1059-1071.	1.3	2
114	Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results. <i>BMC Rheumatology</i> , 2021, 5, 35.	0.6	2
115	Biologics and biosimilars in axial spondyloarthritis: Lots of kids on the block!. <i>Indian Journal of Rheumatology</i> , 2020, 15, 64.	0.2	2
116	Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110514.	1.2	2
117	Comment on: Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?. <i>Rheumatology</i> , 2021, 60, e24-e25.	0.9	2
118	Ultrasound shows swollen joints are the better proxy for synovitis than tender joints in DMARD-naïve early psoriatic arthritis. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab086.	0.3	2
119	Impact of COVID-19 containment measures on patients with rheumatic and musculoskeletal disease in the UK and Europe: the REUMAVID study (phase1). <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab098.	0.3	2
120	SAT0313â€¦The link between enthesitis and arthritis in psoriatic arthritis: A switch to a vascular phenotype at insertions may play a role in arthritis development. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 578.1-578.	0.5	1
121	OP0128â€¦PTPN22 is Associated with Susceptibility to Psoriatic Arthritis but not Psoriasis: Evidence for a Further PSA-Specific Risk Locus. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 116.3-117.	0.5	1
122	SAT0396â€¦Secukinumab Provides Sustained Improvements in The Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from A Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing (Measure 2). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 812.2-813.	0.5	1
123	AB0700â€¦Baseline Clinical Characteristics of The Leeds Sparro Early Psoriatic Arthritis Cohort: High Disease and Radiographic Involvement Are Seen Early Even in The Presence of Preserved Quality of Life: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1144.1-1144.	0.5	1
124	FRI0646â€¦Three-dimensional nail imaging by optical coherence tomography: a novel biomarker of response to therapy for nail disease in psoriasis and psoriatic arthritis. , 2017, , .		1
125	O65â€¦Personalising care: the use of anti-drug antibodies and drug trough levels is a safe and cost-effective treatment strategy in spondyloarthritis. <i>Rheumatology</i> , 2018, 57, .	0.9	1
126	176â€¦Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through three years: long-term results of two randomised double-blind placebo-controlled phase III studies. <i>Rheumatology</i> , 2018, 57, .	0.9	1

#	ARTICLE	IF	CITATIONS
127	O41â€¦TM's not only about treating inflammation: clinical psychology intervention for rheumatology patients remains an unmet need in daily practice. <i>Rheumatology</i> , 2019, 58, .	0.9	1
128	Improving patient care through a collaborative effort in the Leeds Combined Psoriatic Service: an effective provision of multi-specialty input. <i>Rheumatology</i> , 2021, 60, 467-470.	0.9	1
129	POS1175â€¦ASSESSMENT OF THE COVID-19 PANDEMIC FROM THE PERSPECTIVE OF PEOPLE WITH RHEUMATIC MUSCULOSKELETAL DISEASES IN EUROPE. RESULTS FROM THE REUMAVID STUDY (PHASE 1). <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 868-869.	0.5	1
130	OPO252â€¦ARTHRTIS AND ENTHESITIS IN THE HIP AND PELVIS REGION IN SPONDYLOARTHRITIS â€“ VALIDATION OF TWO WHOLE-BODY MRI METHODS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 153.2-154.	0.5	1
131	FRI0286â€¦IXEKIZUMAB TREATMENT IMPROVES FATIGUE, SPINAL PAIN, STIFFNESS, AND SLEEP IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 731-732.	0.5	1
132	Receptor activator of nuclear factor kappa-Î³ ligand (RANKL) serum levels are associated with progression to seropositive/negative rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 456-462.	0.4	1
133	OA35â€¦Efficacy of secukinumab and HLA-B27 subtypes: results from a Phase 3b randomised controlled trial in axial SpA. <i>Rheumatology</i> , 2022, 61, .	0.9	1
134	SAT0355â€¦Observed Incidence Rates of Uveitis following Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 721.3-722.	0.5	0
135	FRI0152â€¦Decreased Employment, Work Productivity, and Presenteeism in Patients with Ankylosing Spondylitis is Associated with Increased Disease Activity as Measured by Basdai: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 437.2-437.	0.5	0
136	A2.16 â€¦Association of 20 interferon related gene expression with response to infliximab treatment in ankylosing spondylitis: Pilot data. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A21.2-A22.	0.5	0
137	O2.18â€¦Can rankl serum levels predict future progression to rheumatoid arthritis in early arthritis clinic patients?. , 2017, , .		0
138	114.â€¦SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING (MEASURE 2). <i>Rheumatology</i> , 2017, 56, .	0.9	0
139	O03â€¦Efficacy and safety of ixekizumab at week 24 in biologic experienced patients with active psoriatic arthritis summary results. <i>Rheumatology</i> , 2018, 57, .	0.9	0
140	P23â€¦Improving the health and wellbeing of young people with inflammatory musculoskeletal disease: implementation of a young persons keyworker within the Leeds rheumatology service. <i>Rheumatology</i> , 2018, 57, .	0.9	0
141	174â€¦Secukinumab demonstrates consistent safety over long-term exposure up to three years in patients with active ankylosing spondylitis: pooled analysis of three Phase III trials. <i>Rheumatology</i> , 2018, 57, .	0.9	0
142	172â€¦Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: three-year results from Phase 3 trial, MEASURE 2. <i>Rheumatology</i> , 2018, 57, .	0.9	0
143	246â€¦Safety and effectiveness of certolizumab pegol in axial spodyloarthritis in a real-world setting: a UK sub-analysis from a European non-interventional study. <i>Rheumatology</i> , 2019, 58, .	0.9	0
144	253â€¦Performance of magnetic resonance imaging in the diagnosis of axial spondyloarthritis: a systematic literature review. <i>Rheumatology</i> , 2019, 58, .	0.9	0

#	ARTICLE	IF	CITATIONS
145	FRI0429â€¦NON TOPICAL PHARMACOLOGICAL TREATMENT OF EARLY, UNTREATED (DMARD-NAËVE, SYSTEMIC) Tj ETQq1 0.7843		0
146	BRITSpA at five. Rheumatology, 2020, 59, 699-701.	0.9	0
147	BSR Spondyloarthritis Course, 27 February 2020. Spondyloarthritis: pathogenesis, diagnosis and management. Rheumatology Advances in Practice, 2020, 4, rkaa043.	0.3	0
148	P83â€¦Improving patient care through a collaborative effort in the Leeds Combined Psoriatic Service: an effective provision of multi-specialty input. Rheumatology, 2020, 59, .	0.9	0
149	AB0675â€¦COUNTRY COMPARISON ON THE IMPACT OF THE COVID-19 PANDEMIC ON PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1). Annals of the Rheumatic Diseases, 2021, 80, 1369-1370.	0.5	0
150	AB0676â€¦FEARS AND HOPES DURING THE COVID-19 PANDEMIC IN PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1). Annals of the Rheumatic Diseases, 2021, 80, 1370-1371.	0.5	0
151	OP0149â€¦RELIABILITY AND RESPONSIVENESS OF TWO OMERACT WHOLE-BODY MRI SCORES OF ENTHESEAL AND JOINT INFLAMMATION IN THE KNEE REGION IN SPONDYLOARTHRITIS. Annals of the Rheumatic Diseases, 2021, 80, 89-90.	0.5	0
152	AB0677â€¦GENDER DIFFERENCES ON THE IMPACT OF THE COVID-19 PANDEMIC AND LOCKDOWN IN PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1). Annals of the Rheumatic Diseases, 2021, 80, 1371-1372.	0.5	0
153	POS1213â€¦IMPACT OF THE COVID-19 PANDEMIC AND LOCKDOWN ON WELLBEING ON PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1). Annals of the Rheumatic Diseases, 2021, 80, 889.2-890.	0.5	0
154	Subjective loss of clinical response to TNFi in axSpA relates to recurrence of MRI bone marrow oedema particularly with long-acting agents. Rheumatology, 2021, , .	0.9	0
155	AB0846â€¦Personalising care: using infliximab drug trough and anti-drug antibody levels improves clinical treatment decisions and is a cost effective strategy in spondyloarthritis. , 2018, , .		0
156	The changing face of psoriatic arthritis. Lancet Rheumatology, The, 2022, 4, e313-e315.	2.2	0
157	Dr Andrew Charles Scott Keat, MBBS MD FRCP (1949-2022). Rheumatology, 0, , .	0.9	0
158	Exploring the role of rheumatic and musculoskeletal disease patient organisations during the COVID-19 pandemic: results from the REUMAVID study (phase 1). Clinical and Experimental Rheumatology, 0, , .	0.4	0
159	Exploring the role of rheumatic and musculoskeletal disease patient organisations during the COVID-19 pandemic: results from the REUMAVID study (phase 1).. Clinical and Experimental Rheumatology, 2022, , .	0.4	0